Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy
Therapeutically relevant doses of CD19/CD22 CAR-T cells can be successfully manufactured from whole blood. On average, 80 mL of whole blood yields enough CAR-T cells to create a single dose for a pediatric patient (50 kg) at a dosage of 1 × 10<sup>6</sup> CAR-T cells/kg. For larger patients, scaling up is straightforward by collecting a larger blood volume. This method also demonstrates a cost-effective approach to T cell activation and expansion which, alongside a more straightforward collection of whole blood, makes it more widely accessible especially for middle- and low-income countries. By reducing costs and labor, this strategy has the potential to significantly expand global access to CAR-T cell therapy.
Authors
- Steven L. Highfill (ORCID: https://orcid.org/0000-0003-0135-0961)
- Nirali N. Shah (ORCID: https://orcid.org/0000-0002-8474-9080)
- Rongye Shi (ORCID: https://orcid.org/0000-0003-4298-9358)
- Bonnie Yates (ORCID: https://orcid.org/0009-0005-4288-3037)
- Alexandra Dreyzin (ORCID: https://orcid.org/0000-0003-1414-290X)
- Sara K. Silbert (ORCID: https://orcid.org/0000-0002-2746-9410)
- Sarah Underwood
- Sarmila Sarkar
- Michaela Procházková (ORCID: https://orcid.org/0000-0002-3773-8995)
- David F. Stroncek (ORCID: https://orcid.org/0000-0001-5867-3265)
- Ping Jin (ORCID: https://orcid.org/0000-0002-3479-7607)
- S. Ramanujam
- Yihua Cai (ORCID: https://orcid.org/0000-0002-3693-9533)
- Hannah Song (ORCID: https://orcid.org/0000-0002-7238-7553)
- Robert Somerville (ORCID: https://orcid.org/0000-0002-3093-2533)
- Roshini Traynor (ORCID: https://orcid.org/0000-0001-6644-0162)
- Isabella Vignola
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- Cytotherapy
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1016/j.jcyt.2024.11.013
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- U.S. Department of Health and Human Services
- Australian Government
- National Institutes of Health
- NIH Clinical Center